Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of Enavogliflozin and Phentermine in Healthy Adults
NCT05321732Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin in obesity (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Peak Plasma Concentration at Steady State at Day 6 and Area Under the Plasma Concentration versus Time Curve at Steady State at Day 6. Status: unknown.
02
Drugs
enavogliflozin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05321732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321732.